These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12364685)

  • 1. Insight into illness and attitudes toward medications among inpatients with schizophrenia.
    Sajatovic M; Rosch DS; Sivec HJ; Sultana D; Smith DA; Alamir S; Buckley P; Bingham CR
    Psychiatr Serv; 2002 Oct; 53(10):1319-21. PubMed ID: 12364685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
    Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
    J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach.
    Santone G; Rucci P; Muratori ML; Monaci A; Ciarafoni C; Borsetti G
    Psychiatry Res; 2008 Apr; 158(3):324-34. PubMed ID: 18262656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia.
    Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F
    Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.
    Freudenreich O; Cather C; Evins AE; Henderson DC; Goff DC
    J Clin Psychiatry; 2004 Oct; 65(10):1372-6. PubMed ID: 15491241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
    Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
    Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.
    Cañas F; Ciudad A; Gutiérrez M; Gibert J; Gascón J; Carrasco JL; Bobes J; Gómez JC; Alvarez E
    Med Clin (Barc); 2005 Apr; 124(13):481-6. PubMed ID: 15847764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.
    Lambert M; Conus P; Eide P; Mass R; Karow A; Moritz S; Golks D; Naber D
    Eur Psychiatry; 2004 Nov; 19(7):415-22. PubMed ID: 15504648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure.
    Kasper JA; Hoge SK; Feucht-Haviar T; Cortina J; Cohen B
    Am J Psychiatry; 1997 Apr; 154(4):483-9. PubMed ID: 9090334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China.
    Mohamed S; Rosenheck R; He H; Yuping N
    Soc Psychiatry Psychiatr Epidemiol; 2014 Jul; 49(7):1063-70. PubMed ID: 24549835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of an adapted Illness Management and Recovery program for people with schizophrenia awaiting discharge from a psychiatric hospital.
    Lin EC; Chan CH; Shao WC; Lin MF; Shiau S; Mueser KT; Huang SC; Wang HS
    Psychiatr Rehabil J; 2013 Dec; 36(4):243-9. PubMed ID: 24320832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
    Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia.
    Suzuki T; Uchida H; Takeuchi H; Nakajima S; Nomura K; Tanabe A; Yagi G; Watanabe K; Kashima H
    Hum Psychopharmacol; 2009 Dec; 24(8):628-38. PubMed ID: 19946935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.